Obesity with cardiovascular disease: The SELECT trial showed benefit in patients with obesity and heart disease regardless of diabetes status, expanding the population who clearly benefit
Understanding its mechanism of action, benefits, usage guidelines, and potential side effects is essential for maximizing its effectiveness and ensuring safe use
We found that the levels of CXCL10 and its downstream effectors, p-JNK, COL1A1, and p-AKT, significantly increased in M38 or B16 group, WCV significantly reduced their levels close to control in VM38 or VB16 group, and PD-1 had no obvious impacts in PM38 or PB16 group (Fig
The pharmacokinetics of GLP-1 receptor agonists create windows of peak activity, troughs of reduced effect, and transition periods where side effects hit hardest
Metabolic rate typically remains stable or increases on GLP-1 therapy, even with intermittent fasting, as long as you avoid chronic undereating